CD86 and neoplasm: Aligned with these reports, our immunomigratome analysis has revealed that tumor-sentinel node migratory CD86/CD40/MHC II/CCR7+ DCs are enhanced by IRT, and CCR7 + DC are essential for the expansion and activation of tumor-specific T cells within the sentinel lymph node to mediate a successful tumor response to immunoradiotherapy.